Serial deep-tech founder and theoretical physicist who builds AI for molecules, materials, and medicines. As co-founder and CSO/CIO of Creyon Bio he built the datasets and machine-learning models that predict the pharmacology of nucleic-acid drugs (ASOs), delivering an N-of-1 medicine from whiteboard to first dosing in under 13 months and co-leading a partnership with Eli Lilly worth up to ~$1B. He now builds polymer and molecular foundation models and glass-box agentic AI systems with collaborators at Stanford and Pitt. He advises teams on AI-for-science and AI-driven drug discovery, nucleic-acid medicine R&D, quantum-chemical and ML featurization of molecules, and how to build and lead high-performing ML and wet-/dry-lab organizations.